COMPANY

NeurOp

HQ: Atlanta, GA source · neuropinc.com ↗ · Southeast

Keywords: psychiatry stroke depression Ischemic Stroke Postoperative Pain Substance Abuse Subarachnoid Hemorrhage Safety Issues alzheimer's disease NP10679

Location: Atlanta, GA · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)20NIH grants

Timeline

Apr 4, 2019 Trial start Phase 1: A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers source ↗
Apr 6, 2018 Trial start Phase 1: Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT04007263	A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers	Phase 1	Completed	Apr 4, 2019	Aug 30, 2019 (actual)
NCT03565861	Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers	Phase 1	Completed	Apr 6, 2018	Sep 2, 2018 (actual)

NIH awards 20

Annual award amounts. Total $10.1M.

Mar 25, 2019 NIH award 3R44NS071657-06S1 FY2019: $125,000 awarded for that fiscal year; activity R44 (SBIR); PI ZACZEK, ROBERT; recipient as written: NEUROP, INC., ATLANTA, GA. Phase 1 Clinical Evaluation of NP10679, a GluN2B Sel source ↗
Aug 21, 2018 NIH award 5R44NS071657-06 FY2018: $1,327,699 awarded for that fiscal year; activity R44 (SBIR); PI ZACZEK, ROBERT; recipient as written: NEUROP, INC., ATLANTA, GA. Phase 1 Clinical Evaluation of NP10679, a GluN2B Sel source ↗
Jul 13, 2018 NIH award 1R41DA046266-01 FY2018: $301,303 awarded for that fiscal year; activity R41 (STTR); PI ZACZEK, ROBERT; recipient as written: NEUROP, INC., ATLANTA, GA. Preclinical assessment of the GluN2B inhibitor clinica source ↗
Jul 18, 2017 NIH award 2R44NS071657-05 FY2017: $2,163,892 awarded for that fiscal year; activity R44 (SBIR); PI ZACZEK, ROBERT; recipient as written: NEUROP, INC., ATLANTA, GA. Phase 1 Clinical Evaluation of NP10679, a GluN2B Sel source ↗
Aug 21, 2015 NIH award 3U44NS071657-04S3 FY2015: $48,422 awarded for that fiscal year; activity U44 (SBIR); PI KOSZALKA, GEORGE WALTER; recipient as written: NEUROP, INC., ATLANTA, GA. Pre-clinical Development of a Context-Depend source ↗
Jun 10, 2015 NIH award 3U44NS071657-04S2 FY2015: $5,000 awarded for that fiscal year; activity U44 (SBIR); PI KOSZALKA, GEORGE WALTER; recipient as written: NEUROP, INC., ATLANTA, GA. Pre-clinical Development of a Context-Depende source ↗
Feb 5, 2015 NIH award 3U44NS071657-04S1 FY2015: $393,610 awarded for that fiscal year; activity U44 (SBIR); PI KOSZALKA, GEORGE WALTER; recipient as written: NEUROP, INC., ATLANTA, GA. Pre-clinical Development of a Context-Depen source ↗
Sep 12, 2014 NIH award 5U44NS071657-04 FY2014: $748,822 awarded for that fiscal year; activity U44 (SBIR); PI KOSZALKA, GEORGE WALTER; recipient as written: NEUROP, INC., ATLANTA, GA. Pre-clinical Development of a Context-Depende source ↗
Sep 10, 2014 NIH award 1R41AG048723-01 FY2014: $219,338 awarded for that fiscal year; activity R41 (STTR); PI MYERS, SCOTT JAMES; recipient as written: NEUROP, INC., ATLANTA, GA. NMDA Receptor Subtype Selective Modualtors as Alzh source ↗
Mar 24, 2014 NIH award 3U44NS071657-03S1 FY2014: $86,250 awarded for that fiscal year; activity U44 (SBIR); PI KOSZALKA, GEORGE WALTER; recipient as written: NEUROP, INC., ATLANTA, GA. Pre-clinical Development of a Context-Depend source ↗
Sep 18, 2013 NIH award 5U44NS071657-03 FY2013: $994,652 awarded for that fiscal year; activity U44 (SBIR); PI KOSZALKA, GEORGE WALTER; recipient as written: NEUROP, INC., ATLANTA, GA. Pre-clinical Development of a Context-Depende source ↗
Mar 25, 2013 NIH award 5R43MH096363-02 FY2013: $346,261 awarded for that fiscal year; activity R43 (SBIR); PI MYERS, SCOTT JAMES; recipient as written: NEUROP, INC., ATLANTA, GA. Optimization of Novel NR2C and NR2D subunit-select source ↗
Aug 9, 2012 NIH award 4U44NS071657-02 FY2012: $931,527 awarded for that fiscal year; activity U44 (SBIR); PI KOSZALKA, GEORGE WALTER; recipient as written: NEUROP, INC., ATLANTA, GA. Pre-clinical Development of a Context-Depende source ↗
Apr 3, 2012 NIH award 1R43MH096363-01 FY2012: $345,731 awarded for that fiscal year; activity R43 (SBIR); PI MYERS, SCOTT JAMES; recipient as written: NEUROP, INC., ATLANTA, GA. Optimization of Novel NR2C and NR2D subunit-select source ↗
Jun 27, 2011 NIH award 1U44NS071657-01A1 FY2011: $299,541 awarded for that fiscal year; activity U44 (SBIR); PI KOSZALKA, GEORGE WALTER; recipient as written: NEUROP, INC., ATLANTA, GA. Pre-clinical Development of a Context-Depen source ↗
Jun 4, 2008 NIH award 1R41NS056856-01A2 FY2008: $144,137 awarded for that fiscal year; activity R41 (STTR); PI LASKOWITZ, DANIEL T; recipient as written: NEUROP, INC., ATLANTA, GA. Evaluation of pH Dependent Neuroprotectants in source ↗
Sep 13, 2007 NIH award 5R44NS049666-03 FY2007: $637,385 awarded for that fiscal year; activity R44 (SBIR); PI MYERS, SCOTT JAMES; recipient as written: NEUROP, INC., ATLANTA, GA. pH-Sensitive Glutamate Receptor Inhibitors: Clinic source ↗
Jan 25, 2007 NIH award 1R43NS057917-01 FY2007: $125,788 awarded for that fiscal year; activity R43 (SBIR); PI MYERS, SCOTT JAMES; recipient as written: NEUROP, INC., ATLANTA, GA. Neuroprotection of pH Sensitive NMDAR Antagonists source ↗
Sep 25, 2006 NIH award 2R44NS049666-02A1 FY2006: $766,198 awarded for that fiscal year; activity R44 (SBIR); PI MYERS, SCOTT JAMES; recipient as written: NEUROP, INC., ATLANTA, GA. pH-Sensitive Glutamate Receptor Inhibitors: Clin source ↗
Sep 20, 2004 NIH award 1R43NS049666-01 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI WASHBURN, MARK S; recipient as written: NEUROP, INC., ATLANTA, GA. In vivo proof of concept:pH-dependent neuroprotectio source ↗